US5401838A - Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides - Google Patents

Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides Download PDF

Info

Publication number
US5401838A
US5401838A US08/044,343 US4434393A US5401838A US 5401838 A US5401838 A US 5401838A US 4434393 A US4434393 A US 4434393A US 5401838 A US5401838 A US 5401838A
Authority
US
United States
Prior art keywords
group
beta
alkyl
halo
anomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/044,343
Inventor
Ta-Sen Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/902,312 external-priority patent/US5371210A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US08/044,343 priority Critical patent/US5401838A/en
Priority to UA93003070A priority patent/UA41261C2/en
Priority to AU41355/93A priority patent/AU659009B2/en
Priority to MYPI93001200A priority patent/MY115775A/en
Priority to CN 93109045 priority patent/CN1040114C/en
Priority to MX9303707A priority patent/MX9303707A/en
Priority to KR1019930011312A priority patent/KR100252452B1/en
Priority to AT93304817T priority patent/ATE158799T1/en
Priority to SG9607939A priority patent/SG94686A1/en
Priority to NZ247939A priority patent/NZ247939A/en
Priority to NO19932288A priority patent/NO180235B3/en
Priority to EP93304817A priority patent/EP0577303B1/en
Priority to DE69314239T priority patent/DE69314239C5/en
Priority to IL106071A priority patent/IL106071A/en
Priority to CY206793A priority patent/CY2067A/en
Priority to ES93304817T priority patent/ES2107624T3/en
Priority to CZ19931233A priority patent/CZ291165B6/en
Priority to HU9301822A priority patent/HUT64358A/en
Priority to PL93299415A priority patent/PL172348B1/en
Priority to CA002098881A priority patent/CA2098881C/en
Priority to FI932869A priority patent/FI108643B/en
Priority to BR9302434A priority patent/BR9302434A/en
Priority to JP14913093A priority patent/JP3313191B2/en
Priority to DK93304817.5T priority patent/DK0577303T3/en
Priority to HU0201196A priority patent/HU223837B1/en
Assigned to ELI LILLY AND COMPANY reassignment ELI LILLY AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOU, TA-SEN
Publication of US5401838A publication Critical patent/US5401838A/en
Application granted granted Critical
Priority to HK97102088A priority patent/HK1000535A1/en
Priority to GR970403339T priority patent/GR3025689T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Definitions

  • the invention pertains to the field of pharmaceutical chemistry and provides a stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides.
  • fusion glycosylation Another type of condensation is fusion glycosylation, which is carried out in the absence of a solvent and at reaction temperatures sufficient to convert the carbohydrate and nucleoside base reactants to a molten phase.
  • the original fusion glycosylation process was used to prepare purine nucleosides and involved reacting a peracylated sugar with a fusible purine base under vacuum and in the presence of a catalyst, such as p-toluenesulfonic acid.
  • a catalyst such as p-toluenesulfonic acid.
  • the glycosylation was not effective in condensing pyrimidine nucleosides because of their high melting points.
  • the yields would vary widely and a broad range of anomerically mixed nucleoside products were produced.
  • purine deoxynucleosides were carried out by the procedure described in Robbins, Nucleic Acids Res., 12, 1179 (1984), and involved reacting a sodium salt of a halopurine with 1-chloro-3,5-ditoluoylribofuranose.
  • the sodium salts of purine bases were found to be much better nucleophiles than silylated pyrimidine bases.
  • U.S. Pat. No. 4,526,988, Hertel illustrated a fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides which involves reacting a 3,5-bis(t-butyldimethylsilyloxy)-1-methanesulfonyloxy-2-deoxy-2,2-difluororibofuranose with 5-methyl-2,4-bis(trimethylsilyloxy)-pyrimidine at 150° C.
  • deoxynucleosides have been prepared in high yield from deoxyhalogenose with Friedel-Crafts catalysts, notably, 1-chloro-2-deoxy-3,5-di-p-toluoyl-alpha-D-erythropentofuranose; see, M. Hofer, Chem. Ber, 93, 2777 (1960).
  • halogenoses are less stable thermally than peracylated carbohydrates and produce a 1:1 alpha to beta-anomeric mixture of nucleoside products.
  • beta-nucleosides could be obtained from 2-deoxy-2-fluoro-3,5-di-O-benzoyl-alpha-O-arabinosyl bromide via S N 2 displacement. Also, stereoselectivity of the nucleoside products could be achieved if either carbon tetrachloride or chloroform solvents was employed.
  • hydroxy protected carbohydrates such as 2-deoxy-2,2-difluoro-D-ribofuranose, containing a methanesulfonate, toluenesulfonate, ethanesulfonate, isopropanesulfonate or 4-methoxybenzenesulfonate leaving group at the C-1 position, were reacted with a protected nucleobase at temperatures of 50° C. to 220° C., in the presence of a high boiling solvent, such as dimethylformamide, dimethylacetamide and hexamethylphosphoramide.
  • a high boiling solvent such as dimethylformamide, dimethylacetamide and hexamethylphosphoramide.
  • Hertel's condensation method provides alpha-anomer stereoselectively and therefore forms a 4:1 alpha to beta anomeric ratio of nucleoside products and goes on to describe an improved procedure, based on the Vorbruggen condensation method, that employs a pivotal intermediate of 2-deoxy-2,2-difluoro-3,5-di-O-benzoyl-alpha-D-arabinosyl methanesulfonate.
  • Chou's condensation method forms a 1:1 alpha to beta anomer mixture of nucleoside products.
  • one object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides.
  • Another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides without the use of a catalyst.
  • Another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides in yields higher than those produced by conventional fusion glycosylation procedures.
  • Yet another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides that offers a means for isolating intermediates of the beta-anomer enriched nucleosides as a crude product or acid addition salt such as a hydrochloride salt.
  • the invention is a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR1## wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase moiety selected from the group consisting of ##STR2## wherein R 1 is selected from the group consisting of hydrogen, alkyl and halo; R 2 is selected from the group consisting of hydrogen, alkyl and halo; Z is a hydroxy protecting group and W is an amino protecting group; comprising reacting an alpha-anomer enriched 2,2-difluorocarbohydrate of the formula ##STR3## wherein Y selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is as defined above; with at least a molar equivalent of a nucleobase derivative, R",
  • the invention is a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR5## wherein X and R' are as defined above; comprising reacting an alpha-anomer enriched 2-monofluorocarbohydrate of the formula ##STR6## wherein Y and X are as defined above; with at least a molar equivalent of a nucleobase derivative, R", wherein R" is as defined above.
  • This invention also provides a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR7## wherein R is a deblocked nucleobase selected from the group consisting of ##STR8## wherein R 1 is selected from the group consisting of hydrogen, alkyl and halo; R 2 is selected from the group consisting of hydrogen, alkyl and halo; comprising reacting a alpha-anomer enriched 2,2-difluorocarbohydrate of the formula ##STR9## wherein Y is selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is a hydroxy protecting group; with at least a molar equivalent of a nucleobase derivative, R"; wherein R" is as defined above; and deblocking.
  • R is a de
  • a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR10## wherein R is a deblocked nucleobase as defined above; comprising reacting a alpha-anomer enriched 2-fluorocarbohydrate of the formula ##STR11## wherein Y is selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is a hydroxy protecting group; with at least a molar equivalent of a nucleobase derivative R", wherein R" is as defined above; and deblocking.
  • xylenes alone or in combination refers to all isomers of xylene and mixtures thereof.
  • lactol alone or in combination refers to a 2-deoxy-2,2-difluoro-D-ribofuranose or 2-deoxy-2-fluoro-D-ribofuranose.
  • carbohydrate alone or in combination refers to an activated lactol wherein the hydroxy group at the C-1 position has been replaced by a desirable leaving group.
  • halo alone or in combination refers to chloro, iodo, fluoro and bromo.
  • alkyl alone or in combination refers to straight, cyclic and branched chain aliphatic hydrocarbon groups which preferably contain up to 7 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl groups and the like or substituted straight, cyclic and branched chain aliphatic hydrocarbons such as chloroethyl, 1,2-dichloroethyl and the like.
  • alkoxy alone or in combination refers to compounds of the general formula AO; wherein A is an alkyl.
  • aryl alone or in combination refers to carbocyclic or heterocyclic groups such as phenyl, naphthyl, thienyl and substituted derivatives thereof.
  • aromatic alone or in combination refers to benzene-like structures containing (4N+2) delocalized ⁇ electrons.
  • substituted alone or in combination refers to a substitution by at least one or more of the groups selected from cyano, halo, carboalkoxy, toluoyl, nitro, alkoxy, alkyl, and dialkylamino.
  • anomer-enriched alone or in combination refers to an anomeric mixture wherein the ratio of a specified alpha- or beta-anomer is greater than 1:1 and includes substantially pure anomer.
  • alpha- or beta-anomer enriched carbohydrates of formulas II and V are reacted with at least a molar equivalent of a nucleobase in the absence of a catalyst and a solvent, as represented in the following reaction schemes for making beta-anomer nucleosides: ##STR12## wherein Y, X, R" and R' are as defined above.
  • the glycosylation reaction proceeds primarily via S N 2 displacement. Therefore, the beta-anomer enriched nucleoside products are derived from alpha-anomer enriched carbohydrates. Conversely, the alpha-anomer enriched nucleoside products are derived from beta-anomer enriched carbohydrates.
  • lactol starting materials suitable for use in the present fusion glycosylation process are commonly known in the art and can be readily synthesized by standard procedures commonly employed by those of ordinary skill in the art.
  • U.S. Pat. No. 4,526,988 teaches the synthesis of 2-deoxy-2,2-difluoro-D-ribofuranoses having the formula ##STR13##
  • RES., 42,233 (1975) teaches the synthesis of 2-deoxy-2-fluoro-D-ribofuranoses of the formula ##STR14##
  • a 2-deoxy-2,2-difluoro-D-ribofuranose-3,5 dibenzoate of formula III is used to prepare the blocked nucleoside products under the present invention.
  • Glycosylation reactions typically require protecting the hydrogen atoms of the hydroxy groups of the lactol of formulas III and VI to prevent the hydroxy groups from reacting with the nucleobase derivative, or being decomposed in some manner.
  • Hydroxy protecting groups (X) suitable for use in the present glycosylation process may be chosen from known protecting groups used in synthetic organic chemistry. Each hydroxy protecting group selected is preferably capable of being efficiently placed on the lactol and easily removed therefrom once the glycosylation reaction is completed. Hydroxy protecting groups known in the art are described in Chapter 3 of Protective Groups in Organic Chemistry, McOmie Ed., Plenum Press, New York (1973), and Chapter 2 of Protective Groups in Organic Synthesis, Green, John, J.
  • ester forming groups such as formyl, acetyl, substituted acetyl, propionyl, butynyl, pivaloyl, 2-chloroacetyl, benzoyl, substituted benzoyl, phenoxycarbonyl, methoxyacetyl; carbonate derivatives such as phenoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, vinyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl and benzyloxycarbonyl; alkyl ether forming groups such as benzyl, diphenylmethyl, triphenylmethyl, t-butyl, methoxymethyl, tetrahydropyranyl, allyl, tetrahydrothienyl, 2-methoxyethoxy methyl; and silyl ether forming groups such as trialkylsilyl, trimethylsilyl, isopropyldialky
  • each hydroxy protecting group (X) In attaching each hydroxy protecting group (X) to the lactol, typical reaction conditions are employed and depend on the nature of the protecting group chosen. Suitable reaction conditions are discussed in U.S. Pat. No. 4,526,988 which is incorporated herein by reference.
  • an appropriate leaving group is stereoselectively attached to the lactol of formulas III and VI which activates the lactol and generates the and alpha-anomer enriched carbohydrate of formulas II and V.
  • the leaving group (Y) of the carbohydrate may be selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy; provided that trifluoromethanesulfonyloxy, 1,1,1-trifluoroethanesulfonyloxy, octafluorobutanesulfonyloxy (C 4 F 8 HSO 3 ) and nanofluorobutanesulfonyloxy (C 4 F 9 SO 3 ) are not used; however, more preferred are methanesulfonyloxy, 2-chloroethanesulfonyloxy, toluenesulfonyloxy, p-nitrobenzenesulfonyloxy and p-bromobenzenesulfonyloxy; while most preferred is methanesulfonyloxy.
  • the alpha-anomer enriched carbohydrate of formula II may be prepared by one of two methods.
  • the alpha-anomer enriched carbohydrate of formula V is prepared by the second of these methods.
  • the first method described in U.S. Pat. No. 5,256,798, teaches treating a beta-anomer ribofuranosyl sulfonate or anomeric mixture thereof with a source of a conjugate anion of a sulfonic acid at elevated temperatures in an inert solvent.
  • the second method is described in pending U.S. patent application Ser. No.
  • the amine base preferably has a pKa of from about 8 to about 20 and is employed in a range of from about 1 molar equivalent to about 2 molar equivalents and more preferably from about 1.2 molar equivalents to about 1.5 molar equivalents.
  • the reaction is carried out in an inert solvent having a freezing point temperature preferably below -78° C.
  • Preferred solvents are selected from the group consisting of dichloromethane, 1,2-dichloroethane, dichlorofluoromethane, acetone, toluene, anisole, chlorobenzene, and mixtures thereof.
  • the temperature of the solvent mixture is adjusted preferably in the range from about -40° C. to about -120° C. and more preferably below about -78° C.
  • the low temperature shifts the alpha to beta anomeric ratio of the lactol in favor of the alpha-anomer in a range from about 2:1 to about 4:1 alpha to beta.
  • a compound of formula III where X is benzoyl, was added to dichloromethane and triethylamine at room temperature for 30 minutes. Next, the temperature of the solvent mixture was lowered.
  • the ionized lactol is then trapped in solution at the low temperature and higher alpha-anomer ratio by adding a sulfonating reagent which forms an alpha-anomer enriched carbohydrate.
  • the sulfonating reagents are selected from the group consisting of substituted and unsubstituted alkyl- and aryl-sulfonyl halides and alkyl- and arylsulfonic acid anhydrides such as methanesulfonyl chloride, depending on the leaving group desired.
  • the alpha-anomer enriched carbohydrate may be isolated in substantially pure form; i.e. greater 95 percent purity; by the procedure described in U.S. Pat. No. 5,256,797.
  • the method requires warming an anomeric mixture of carbohydrates in a solvent from about 30° C. to about 70° C. to form a supersaturated solution.
  • the solvent may be selected from the group consisting of 1,2-dichloroethane, anisole, glyme, and mixtures thereof.
  • the carbohydrate form a precipitate when the temperature of the solution is lowered and a counter solvent is added.
  • the counter solvent may be selected from the group consisting of methanol, ethanol, toluene, ether, dichloromethane, and mixtures thereof.
  • the resulting carbohydrate crystals are then recovered from the solution and dried.
  • nucleobases (R) employed herein are commonly known to organic chemists and no discussion of their synthesis is necessary. However, in order to be useful in the present glycosylation process, the nucleobase derivatives or their tautomeric equivalents bearing amino or hydroxy groups, preferably contain a protecting group, such as amino protecting groups (W) and/or hydroxy protecting groups (Z), depending on the nature of the nucleobase derivative.
  • the protecting group blocks the hydroxy or amino group which may provide a competing reaction site for the alpha-anomer carbohydrate.
  • the protecting groups are attached to the nucleobase derivative (R' ) which is reacted with the beta- or alpha-anomer enriched carbohydrate of formulas II and V and are removed subsequent thereto.
  • a procedure for protecting nucleobase derivatives is described in U.S. Pat. No. 4,526,988.
  • Preferred amino protecting groups (W) for pyrimidine nucleobase derivatives are selected from the group consisting of silyl ether forming groups such as trialkylsilyl, t-butyldialkylsilyl and t-butyldiarylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl; formyl, acetyl, benzoyl and pivalamido; ether forming groups such as methoxymethyl, t-butyl, benzyl, allyl and tetrahydropyranyl; more preferred is trimethylsilyl.
  • silyl ether forming groups such as trialkylsilyl, t-butyldialkylsilyl and t-butyldiarylsilyl
  • carbamates such as t-butoxycarbonyl, benzyloxycarbonyl
  • Preferred amino protecting groups (W) for purine nucleobase derivatives are selected from the group consisting of alkylcarboxamides, haloalkylcarboxamides and arylcarboxamides such as 2-trialkylsilylethoxymethyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, t-butyl, phthalamido, tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl ether, methoxythiomethyl, trityl, pivalamido, t-butyldimethylsilyl, t-hexyldimethylsilyl, triisopropylsilyl, trichloroethoxycarbonyl, trifluoroacetyl, naphthoyl, formyl, acetyl; sulfonamides such as alkylsulfonamido and arylsulfonamido, and more preferred is pi
  • the pivalamido protecting group increases the solubility of notoriously insoluble purine nucleobase derivatives and directs the N-glycosidic coupling of the purine bases to the 9 regioisomer as opposed to the 7 regioisomer.
  • Preferred hydroxy protecting groups (Z) for pyrimidine nucleobase derivatives are selected from silyl ether forming groups such as trialkylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl; carbocyclic esters such as formyl, acetyl, and pivalamido; preferred is trimethylsilyl.
  • Preferred hydroxy protecting groups (Z) for purine nucleobase derivatives are selected from the group consisting of ether forming groups such as benzyl, t-butyl, trityl, tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, trityl; esters such as formyl, acetylpropiorl, pivalamido, benzoyl, substituted benzoyl; carbonates such as carbobenzoxy, t-butoxycarbonyl, carbethoxy, vinyloxycarbonyl; carbamates, such as N,N-dialkylcarbamoyl; trialkylsilyl ethers such as t-butyltrimethylsilyl, t-hexyldimethylsilyl, triisopropylsilyl; more preferred is pivalamido.
  • ether forming groups such as benzyl, t-butyl, trityl, tetra
  • the protecting group itself may be protected.
  • N-acetylcytosine may be protected with trimethylsilyl to give bis-trimethylsilyl-N-acetylcytosine.
  • nucleobase derivative (R) is of the formula ##STR15## wherein Z and W are trimethylsilyl.
  • the nucleobase derivative (R") must be employed in an equimolar amount, relative to the amount of carbohydrate employed. However, it is more preferable to use an excess of nucleobase derivative ranging from about 3 molar equivalents to 30 molar equivalents; more preferably from about 10 molar equivalents to 20 molar equivalents; and most preferably from about 15 molar equivalents to about 20 molar equivalents. In preparing alpha-anomer enriched nucleosides by the present process a smaller amount of nucleobase derivative may be employed in amounts from about 1.5 molar equivalents to about 10 molar equivalents.
  • the reaction between the beta- and alpha-anomer enriched carbohydrate of formulas II and V and the nucleobase derivative be carried out in a dry atmosphere, e.g. in dry air, nitrogen or argon. This is because certain nucleobase derivatives such as silylated nucleobase derivatives, are moisture sensitive.
  • the temperature employed in the fusion glycosylation reaction must be sufficient to convert the carbohydrate of formulas II and V and the nucleobase derivative to a molten phase. Therefore, the temperature ranges from about 100° C. to about 160° C. However, a reaction temperature of about 110° C. to about 150° C. is more preferred; while about 130° C. to about 150° C. is most preferred.
  • the glycosylation reaction is preferably carried out under atmospheric conditions and is substantially complete in about 15 minutes to about 2 hours.
  • HPLC high pressure liquid chromatography
  • TLC thin layer chromatography
  • the beta-anomer enriched nucleosides are prepared in an alpha to beta anomer ratio greater than 1:1 to about 9:1.
  • the final phase of the reaction sequence is the removal of the protecting groups X, Z and/or W from the blocked nucleoside of formula I or IV.
  • the same anomeric ratio of unprotected nucleoside is obtained by removal of the protecting groups.
  • silyl and silyl-amino protecting groups are easily cleaved by use of a protic solvent, such as water or an alcohol.
  • the acyl protecting groups such as benzoyl and the acyl-amino protecting groups, are removed by hydrolysis with a strong base at a temperature from about 0° C. to about 100° C.
  • Strong or moderately strong bases suitable for use in this reaction are bases which have a pKa (at 25° C.) of about 8.5 to about 20.0.
  • Such bases include alkali metal hydroxides such as sodium or potassium hydroxide; alkali metal alkoxides such as sodium methoxide or potassium t-butoxide; alkali metal amides; amines such as diethylamine, hydroxylamine, ammonia and the like; and other common bases such as hydrazine and the like. At least one equivalent of base is needed for each protecting group.
  • the acyl protecting groups can also be removed with acid catalysts, such as methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or with acidic ion exchange resins. It is preferred to carry out such hydrolysis at relatively high temperature, such as the reflux temperature of the mixture, but temperatures as low as ambient may be used when particularly strong acids are used.
  • acid catalysts such as methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or with acidic ion exchange resins. It is preferred to carry out such hydrolysis at relatively high temperature, such as the reflux temperature of the mixture, but temperatures as low as ambient may be used when particularly strong acids are used.
  • ether protecting groups are carried out by known methods, for example, with ethanethiol and aluminum chloride.
  • the t-butyldimethylsilyl protecting group requires acid conditions, such as contact with gaseous hydrogen halide, for its removal.
  • Removal of the protecting groups may be conveniently carried out in alcoholic solvents, especially aqueous alkanols such as methanol.
  • the deblocking reaction may also be carried out in any convenient solvent, such as polyols including ethylene glycol, ethers such as tetrahydrofuran, ketones such as acetone and methyl ethyl ketone, or dimethylsulfoxide.
  • the deblocking reaction employs ammonia to remove a benzoyl hydroxy-protecting group at a temperature of about 10° C. It is preferable, however, to use an excess of base in this reaction, although the amount of excess base used is not crucial.
  • the resulting beta-anomer enriched nucleosides of formula VI or VII may be extracted and/or isolated from the reaction mixture by the procedure described in U.S. Pat. No. 4,965,374, which is incorporated herein by reference.
  • Bis-trimethylsilylcytosine was prepared by combining 292 mg of cytosine with 2 ml of hexamethyldisilazane, 11 mg of ammonium sulfate and 5 ml of xylenes and refluxing the solution for one hour to form a homogenous solution. The excess xylenes and hexamethyldisilazane were removed leaving behind a molten residue of bis-trimethylsilylcytosine.
  • reaction mixture was cooled, diluted in 50 ml of ethyl acetate and washed with 50 ml of 1 N hydrochloric acid.
  • Bis-trimethylsilyluracil was prepared by combining 295 mg of uracil with 5 ml of hexamethyldisilazane, 11 mg of ammonium sulfate and 10 ml of 1,2-dichloroethane. The solution was heated to 110° C. for one hour to form a homogenous solution and the excess xylenes and hexamethyldisilazane were removed to form molten bis-trimethylsilyluracil. 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1- ⁇ -methanesulfonate were added to the molten bis-trimethylsilyluracil. The temperature of the reaction mixture was maintained at 150° C. for 2 hours. HPLC analysis confirmed completion of the reaction. The alpha to beta anomeric ratio of blocked nucleoside product was 1:1.8.
  • reaction mixture was cooled, diluted in 50 ml of ethyl acetate and washed with 50 ml of 1N hydrochloric acid.
  • the reaction mixture was diluted with 100 ml ethyl acetate and washed with 100 ml of 1N hydrochloric acid.
  • a quantitative HPLC analysis of the organic layer indicated that the yield of blocked beta-anomer nucleoside was 50 percent.
  • the reaction mixture was cooled, diluted with 25 ml ethyl acetate and washed with 25 ml of 1 N hydrochloric acid. The aqueous layer was washed with 30 ml of ethyl acetate. A quantitative HPLC analysis of the ethyl acetate layer indicated that the yield of blocked beta-anomer nucleoside was 34 percent.
  • the reaction mixture was cooled, diluted with 20 ml ethyl acetate and washed with 20 ml of 1N hydrochloric acid. The ethyl acetate layer was washed with 20 ml of water. A quantitative HPLC analysis of the ethyl acetate layer indicated that the yield of blocked alpha-anomer nucleoside was 80 percent.
  • reaction mixture was cooled, diluted with 50 ml ethyl acetate and washed with 50 ml of 1N hydrochloric acid.
  • reaction mixture was cooled, diluted with 100 ml ethyl acetate and washed with 100 ml of 1N hydrochloric acid.
  • the reaction mixture was cooled, diluted with 25 ml ethyl acetate and washed with 25 ml of 1N hydrochloric acid. The two layers were separated and the aqueous layer was washed with 30 ml of ethyl acetate.
  • a quantitative HPLC analysis of the combined ethyl acetate layers indicated that the yield of blocked alpha-anomer nucleoside was 75 percent.
  • the reaction mixture was diluted with 40 ml ethyl acetate and washed with 25 ml of 1N hydrochloric acid.
  • a quantitative HPLC analysis of the organic layer indicated that the yield of beta-anomer nucleoside was 27 percent.
  • Bis-trimethylsilylcytosine was prepared by combining 4.9 g of cytosine with 90 ml of hexamethyldisilazane, 581 mg of ammonium sulfate and 2 ml of xylenes and heating the solution for two hours to form a homogenous solution. The excess hexamethyldisilazane was removed and a white residue formed. 1 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1- ⁇ -methanesulfonate, dissolved in 5 ml of acetonitrile, was added to the bis-trimethylsilylcytosine solution and the acetonitrile removed. The temperature of the reaction mixture was maintained at 130° C. under vacuum for 1 hour. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 3.9:1.
  • the reaction mixture was diluted with 100 ml dichloromethane and washed sequentially with 100 ml of 1N hydrochloric acid and 200 ml of 5% sodium bicarbonate followed by 200 ml of saturated sodium chloride. The organic layer was dried over magnesium sulfate, filtered and evaporated to 1.03 g of a yellow solid. A quantitative HPLC analysis indicated that the yield of beta-anomer nucleoside was 43 percent.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

A stereoselective fusion glycosylation process for prearing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleotides and 2'-deoxy-2'-fluoronucleosides by reacting an alpha-anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorcarbohydrate with at least a 3 molar equivalent of a nucleobase derivative at a temperature sufficient to melt the carbohydrate and nucleobase derivative.

Description

CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of Ser. No. 07/902,312, filed Jun. 22, 1992.
BACKGROUND OF THE INVENTION Field of the Invention
The invention pertains to the field of pharmaceutical chemistry and provides a stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides.
State Of the Art
The continued interest in the synthesis of 2'-deoxynucleosides and their analogues is reflected in their successful use as therapeutic agents in viral and cancerous diseases. A critical step in the synthesis of 2'-deoxynucleosides is the condensation of the nucleobase and carbohydrate to form the N-glycosidic bond. When the carbohydrate possesses a 2-hydroxy substituent, the substituent provides a substantial degree of 1,2-anchiomeric assistance, which facilitates stereoselective glycosylation. However, processes for synthesizing of 2'-deoxynucleosides are typically non-stereoselective and form a mixture of alpha and beta nucleosides.
Another type of condensation is fusion glycosylation, which is carried out in the absence of a solvent and at reaction temperatures sufficient to convert the carbohydrate and nucleoside base reactants to a molten phase. The original fusion glycosylation process was used to prepare purine nucleosides and involved reacting a peracylated sugar with a fusible purine base under vacuum and in the presence of a catalyst, such as p-toluenesulfonic acid. However, the glycosylation was not effective in condensing pyrimidine nucleosides because of their high melting points. In addition, the yields would vary widely and a broad range of anomerically mixed nucleoside products were produced.
T. Shimadate, et al., in Nippon Kagaku Zasshi, 81, 1440-1444 (1960) and Chem. Abstracts, 56, 11692 (1962), described a fusion glycosylation process involving reacting a peracylated arabinofuranose and a purine base in the molten phase, under vacuum, in the presence of a p-toluenesulfonic acid catalyst. T. Shimadate, Nippon Kagaku Zasshi, 92, 1268-1270 (1961), described a similar fusion glycosylation process using an anhydrous zinc dichloride catalyst.
R. P. Hodge, et al., J. Org. Chem., 56, 1553-1564 (1991), described the preparation of deoxythymidine, deoxycytidine, deoxyadenosine and deoxyguanosine nucleosides containing deuterium at the C-1' position of the carbohydrate 1-chloro-3,5-ditoluoylribofuranose. The glycosylation was based on the synthesis described in Hubbard, et al., Nucleic Acids Res., 12, 6827 (1984). The preparation of 2'-deoxycytidine required converting a silylated uridine derivative to a silylated cytidine derivative by one of the three different methods. In each, substantial quantities of undesirable alpha-anomer nucleoside product formed. Also, isolating the small quantity of beta-anomer nucleoside obtained from the anomeric mixture proved to be difficult.
The synthesis of purine deoxynucleosides was carried out by the procedure described in Robbins, Nucleic Acids Res., 12, 1179 (1984), and involved reacting a sodium salt of a halopurine with 1-chloro-3,5-ditoluoylribofuranose. The sodium salts of purine bases were found to be much better nucleophiles than silylated pyrimidine bases.
U.S. Pat. No. 4,526,988, Hertel, illustrated a fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides which involves reacting a 3,5-bis(t-butyldimethylsilyloxy)-1-methanesulfonyloxy-2-deoxy-2,2-difluororibofuranose with 5-methyl-2,4-bis(trimethylsilyloxy)-pyrimidine at 150° C.
Vorbruggen, et al., J. Org. Chem., 41, 2084 (1976) provided an outstanding development in the field of glycosylation and showed how nucleosides may be obtained from the Friedel-Crafts catalyzed reaction of a peracylated carbohydrate and silylated heterocycles in a solvent such as, 1,2-dichloroethane and acetonitrile. But when this process was applied to the synthesis 2'-deoxynucleosides, a 1:1 alpha to beta-anomeric mixture of nucleoside products was produced. Recent reports, for example, Grienyl, et. al., J. Med. Chem,, 28, 1679 (1985), have indicated that condensation reactions carried out in chloroform show a preference for beta-anomer nucleosides in a 3:1 beta to alpha ratio.
Some deoxynucleosides have been prepared in high yield from deoxyhalogenose with Friedel-Crafts catalysts, notably, 1-chloro-2-deoxy-3,5-di-p-toluoyl-alpha-D-erythropentofuranose; see, M. Hofer, Chem. Ber, 93, 2777 (1960). However, halogenoses are less stable thermally than peracylated carbohydrates and produce a 1:1 alpha to beta-anomeric mixture of nucleoside products. Walker, et al., Nucleic Acid Research, 12, 6827 (1984), used halogenose in condensation reactions to study the factors controlling the anomeric ratio of nucleoside products and found that beta-anomer nucleosides were formed exclusively from alpha-halocarbohydrates via SN 2 displacement. The corresponding alpha-anomer nucleoside contamination was determined to result from the anomerization of alpha-halo carbohydrate to beta-halo carbohydrate before the SN 2 displacement reaction. Walker et al., found that by changing the solvent or catalyst higher yields of the desired beta-anomer nucleoside were produced.
R. P. Hodge et. al., J. Org. Chem., 6., 1553 (1991), described preparing pyrimidine and purine nucleosides containing deuterium at the C-1' position by the method described by Walker, et al. 1'-Deuterium-2'-deoxycytidine was prepared by reacting a carbohydrate and silylated cytosine derivative but the reaction gave poor yields. However, the yield was significantly improved when silylated uridine derivatives were used.
The synthesis of 2'-deoxy-2'-fluoronucleosides advanced rapidly when a procedure for synthesizing 2-deoxy-2-fluoro-3,5-di-O-benzoyl-alpha-D-arabinosyl bromide was made available; see Tann, et. al., J. Org. Chem., 50, 3644 (1985) and Howell, et. al., J. Org, Chem., 53, 85 (1988). It was discovered that 2-deoxy-2-fluoro-3,5-di-O-benzoyl-alpha-D-arabinosyl bromide did not anomerize in dry acetonitrile over extended periods. Therefore, high yields of beta-nucleosides could be obtained from 2-deoxy-2-fluoro-3,5-di-O-benzoyl-alpha-O-arabinosyl bromide via SN 2 displacement. Also, stereoselectivity of the nucleoside products could be achieved if either carbon tetrachloride or chloroform solvents was employed.
The formation of the N-glycoside bond in 2'-deoxy-2',2'-difluoronucleoside synthesis is much more difficult than in instances where the carbohydrate is 1,2-anchiomericly assisted or contains 2-deoxy-2-fluoro groups. The traditional carbohydrate leaving groups, such as those used in the Vorbruggen condensation method, acetate, chloride and bromide, render the carbohydrate inactive. In order to overcome this problem, Hertel, U.S. Pat. No. 4,526,988, described a modified version of the Vorbruggen condensation method that relied on more reactive sulfonate leaving groups attached to the carbohydrate to affect its reactivity. For example, hydroxy protected carbohydrates, such as 2-deoxy-2,2-difluoro-D-ribofuranose, containing a methanesulfonate, toluenesulfonate, ethanesulfonate, isopropanesulfonate or 4-methoxybenzenesulfonate leaving group at the C-1 position, were reacted with a protected nucleobase at temperatures of 50° C. to 220° C., in the presence of a high boiling solvent, such as dimethylformamide, dimethylacetamide and hexamethylphosphoramide. Hertel teaches that when carrying out the glycosylation reaction at elevated pressures, any convenient inert solvent, such as ethers, halogenated alkanes, and aromatics, can be used since the elevated pressure eliminates the loss of low boiling inert solvents due to evaporation. However, at reaction temperatures from room temperature to 100° C., a catalyst such as trifluoromethanesulfonyloxysilane, is required. U.S. Pat. No. 4,965,374, Chou, et al. reports that Hertel's condensation method provides alpha-anomer stereoselectively and therefore forms a 4:1 alpha to beta anomeric ratio of nucleoside products and goes on to describe an improved procedure, based on the Vorbruggen condensation method, that employs a pivotal intermediate of 2-deoxy-2,2-difluoro-3,5-di-O-benzoyl-alpha-D-arabinosyl methanesulfonate. However, Chou's condensation method forms a 1:1 alpha to beta anomer mixture of nucleoside products.
Despite the preceding advances in nucleoside synthesis, there continues to be a need for a stereoselective fusion glycosylation process capable of efficiently producing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides in increased yields.
Accordingly, one object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides.
Another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides without the use of a catalyst.
Another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides in yields higher than those produced by conventional fusion glycosylation procedures.
Yet another object of the present invention is to provide a stereoselective fusion glycosylation process for preparing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleosides that offers a means for isolating intermediates of the beta-anomer enriched nucleosides as a crude product or acid addition salt such as a hydrochloride salt.
Other objects and advantages of the present invention will become apparent from the following description of embodiments.
SUMMARY OF THE INVENTION
The invention is a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR1## wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase moiety selected from the group consisting of ##STR2## wherein R1 is selected from the group consisting of hydrogen, alkyl and halo; R2 is selected from the group consisting of hydrogen, alkyl and halo; Z is a hydroxy protecting group and W is an amino protecting group; comprising reacting an alpha-anomer enriched 2,2-difluorocarbohydrate of the formula ##STR3## wherein Y selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is as defined above; with at least a molar equivalent of a nucleobase derivative, R", selected from the group consisting of ##STR4## wherein R1, R2, Z and W are as defined above.
In another aspect, the invention is a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR5## wherein X and R' are as defined above; comprising reacting an alpha-anomer enriched 2-monofluorocarbohydrate of the formula ##STR6## wherein Y and X are as defined above; with at least a molar equivalent of a nucleobase derivative, R", wherein R" is as defined above.
This invention also provides a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR7## wherein R is a deblocked nucleobase selected from the group consisting of ##STR8## wherein R1 is selected from the group consisting of hydrogen, alkyl and halo; R2 is selected from the group consisting of hydrogen, alkyl and halo; comprising reacting a alpha-anomer enriched 2,2-difluorocarbohydrate of the formula ##STR9## wherein Y is selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is a hydroxy protecting group; with at least a molar equivalent of a nucleobase derivative, R"; wherein R" is as defined above; and deblocking.
Also provided is a stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR10## wherein R is a deblocked nucleobase as defined above; comprising reacting a alpha-anomer enriched 2-fluorocarbohydrate of the formula ##STR11## wherein Y is selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy and X is a hydroxy protecting group; with at least a molar equivalent of a nucleobase derivative R", wherein R" is as defined above; and deblocking.
DETAILED DESCRIPTION OF THE INVENTION
Throughout this document, all temperatures are in degrees Celsius, all proportions, percentages and the like, are in weight units and all mixtures are in volume units, except where otherwise indicated. Anomeric mixtures are expressed as a weight/weight ratio or percent. The term "xylenes" alone or in combination refers to all isomers of xylene and mixtures thereof. The term "lactol" alone or in combination refers to a 2-deoxy-2,2-difluoro-D-ribofuranose or 2-deoxy-2-fluoro-D-ribofuranose. The term "carbohydrate" alone or in combination refers to an activated lactol wherein the hydroxy group at the C-1 position has been replaced by a desirable leaving group. The term "halo" alone or in combination refers to chloro, iodo, fluoro and bromo. The term "alkyl" alone or in combination refers to straight, cyclic and branched chain aliphatic hydrocarbon groups which preferably contain up to 7 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl groups and the like or substituted straight, cyclic and branched chain aliphatic hydrocarbons such as chloroethyl, 1,2-dichloroethyl and the like. The term "alkoxy" alone or in combination refers to compounds of the general formula AO; wherein A is an alkyl. The term "aryl" alone or in combination refers to carbocyclic or heterocyclic groups such as phenyl, naphthyl, thienyl and substituted derivatives thereof. The term "aromatic" alone or in combination refers to benzene-like structures containing (4N+2) delocalized π electrons. The terms "sulfonate" or sulfonyloxy" alone or in combination refer to compounds of the general formula BSO3, wherein B is alkyl or aryl. The term "substituted" alone or in combination refers to a substitution by at least one or more of the groups selected from cyano, halo, carboalkoxy, toluoyl, nitro, alkoxy, alkyl, and dialkylamino. The phrase "anomer-enriched" alone or in combination refers to an anomeric mixture wherein the ratio of a specified alpha- or beta-anomer is greater than 1:1 and includes substantially pure anomer.
In accordance with the present fusion glycosylation process for preparing beta- and alpha-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides of formulas I and IV, alpha- or beta-anomer enriched carbohydrates of formulas II and V are reacted with at least a molar equivalent of a nucleobase in the absence of a catalyst and a solvent, as represented in the following reaction schemes for making beta-anomer nucleosides: ##STR12## wherein Y, X, R" and R' are as defined above.
While not wishing to be bound by theory, it is believed that the glycosylation reaction proceeds primarily via SN 2 displacement. Therefore, the beta-anomer enriched nucleoside products are derived from alpha-anomer enriched carbohydrates. Conversely, the alpha-anomer enriched nucleoside products are derived from beta-anomer enriched carbohydrates.
The lactol starting materials suitable for use in the present fusion glycosylation process are commonly known in the art and can be readily synthesized by standard procedures commonly employed by those of ordinary skill in the art. For example, U.S. Pat. No. 4,526,988, teaches the synthesis of 2-deoxy-2,2-difluoro-D-ribofuranoses having the formula ##STR13## In addition, Reichman, et al., carbohydr. RES., 42,233 (1975) teaches the synthesis of 2-deoxy-2-fluoro-D-ribofuranoses of the formula ##STR14## In a preferred embodiment, a 2-deoxy-2,2-difluoro-D-ribofuranose-3,5 dibenzoate of formula III is used to prepare the blocked nucleoside products under the present invention.
Glycosylation reactions typically require protecting the hydrogen atoms of the hydroxy groups of the lactol of formulas III and VI to prevent the hydroxy groups from reacting with the nucleobase derivative, or being decomposed in some manner. Hydroxy protecting groups (X) suitable for use in the present glycosylation process may be chosen from known protecting groups used in synthetic organic chemistry. Each hydroxy protecting group selected is preferably capable of being efficiently placed on the lactol and easily removed therefrom once the glycosylation reaction is completed. Hydroxy protecting groups known in the art are described in Chapter 3 of Protective Groups in Organic Chemistry, McOmie Ed., Plenum Press, New York (1973), and Chapter 2 of Protective Groups in Organic Synthesis, Green, John, J. Wiley and Sons, New York (1981); preferred are ester forming groups such as formyl, acetyl, substituted acetyl, propionyl, butynyl, pivaloyl, 2-chloroacetyl, benzoyl, substituted benzoyl, phenoxycarbonyl, methoxyacetyl; carbonate derivatives such as phenoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, vinyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl and benzyloxycarbonyl; alkyl ether forming groups such as benzyl, diphenylmethyl, triphenylmethyl, t-butyl, methoxymethyl, tetrahydropyranyl, allyl, tetrahydrothienyl, 2-methoxyethoxy methyl; and silyl ether forming groups such as trialkylsilyl, trimethylsilyl, isopropyldialkylsilyl, alkyldiisopropylsilyl, triisopropylsilyl, t-butyldialkylsilyl and 1,1,3,3-tetraisopropyldisloxanyl; carbamates such as N-phenylcarbamate and N-imidazoylcarbamate; however more preferred are benzoyl, mono-substituted benzoyl and disubstituted benzoyl, acetyl, pivaloyl, triphenylmethyl ethers, and silyl ether forming groups, especially t-butyldimethylsilyl; while most preferred is benzoyl.
In attaching each hydroxy protecting group (X) to the lactol, typical reaction conditions are employed and depend on the nature of the protecting group chosen. Suitable reaction conditions are discussed in U.S. Pat. No. 4,526,988 which is incorporated herein by reference.
To obtain an efficient reaction of the nucleobase derivative and carbohydrate, an appropriate leaving group is stereoselectively attached to the lactol of formulas III and VI which activates the lactol and generates the and alpha-anomer enriched carbohydrate of formulas II and V. The leaving group (Y) of the carbohydrate may be selected from the group consisting of alkylsulfonyloxy, arylsulfonyloxy, substituted alkylsulfonyloxy and substituted arylsulfonyloxy; provided that trifluoromethanesulfonyloxy, 1,1,1-trifluoroethanesulfonyloxy, octafluorobutanesulfonyloxy (C4 F8 HSO3) and nanofluorobutanesulfonyloxy (C4 F9 SO3) are not used; however, more preferred are methanesulfonyloxy, 2-chloroethanesulfonyloxy, toluenesulfonyloxy, p-nitrobenzenesulfonyloxy and p-bromobenzenesulfonyloxy; while most preferred is methanesulfonyloxy.
The alpha-anomer enriched carbohydrate of formula II may be prepared by one of two methods. The alpha-anomer enriched carbohydrate of formula V is prepared by the second of these methods. The first method, described in U.S. Pat. No. 5,256,798, teaches treating a beta-anomer ribofuranosyl sulfonate or anomeric mixture thereof with a source of a conjugate anion of a sulfonic acid at elevated temperatures in an inert solvent. The second method is described in pending U.S. patent application Ser. No. 07/902,301, Attorney Docket X-8623, and teaches reacting the lactol of formulas III and VI, with an amine base such as triethylamine, tributylamine, dibutylamine, diethylmethylamine, dimethylethylamine, benzylmethylamine, N-methylmorpholine, tripropylamine, dipropylethylamine, N,N-dimethylbenzylamine, diisopropylethylamine, diethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene and 1,5-diazabicyclo[4.3.0]non-5-ene. The amine base preferably has a pKa of from about 8 to about 20 and is employed in a range of from about 1 molar equivalent to about 2 molar equivalents and more preferably from about 1.2 molar equivalents to about 1.5 molar equivalents. The reaction is carried out in an inert solvent having a freezing point temperature preferably below -78° C. Preferred solvents are selected from the group consisting of dichloromethane, 1,2-dichloroethane, dichlorofluoromethane, acetone, toluene, anisole, chlorobenzene, and mixtures thereof. The temperature of the solvent mixture is adjusted preferably in the range from about -40° C. to about -120° C. and more preferably below about -78° C. While not wishing to be bound by theory it is believed that the low temperature shifts the alpha to beta anomeric ratio of the lactol in favor of the alpha-anomer in a range from about 2:1 to about 4:1 alpha to beta. For example, a compound of formula III, where X is benzoyl, was added to dichloromethane and triethylamine at room temperature for 30 minutes. Next, the temperature of the solvent mixture was lowered. An 19 F NMR, taken at various temperatures, shows an increase in the alpha to beta ratio of the ionized lactol as the temperature was lowered:
______________________________________                                    
Temperature   Alpha/Beta Ratio                                            
______________________________________                                    
 19° C.                                                            
              2.0:1                                                       
 -3° C.                                                            
              2.3:1                                                       
-23° C.                                                            
              2.5:1                                                       
-43° C.                                                            
              3.0:1                                                       
-63° C.                                                            
              3.6:1                                                       
-83° C.                                                            
              4.4:1                                                       
______________________________________                                    
The ionized lactol is then trapped in solution at the low temperature and higher alpha-anomer ratio by adding a sulfonating reagent which forms an alpha-anomer enriched carbohydrate. The sulfonating reagents are selected from the group consisting of substituted and unsubstituted alkyl- and aryl-sulfonyl halides and alkyl- and arylsulfonic acid anhydrides such as methanesulfonyl chloride, depending on the leaving group desired.
The alpha-anomer enriched carbohydrate may be isolated in substantially pure form; i.e. greater 95 percent purity; by the procedure described in U.S. Pat. No. 5,256,797. The method requires warming an anomeric mixture of carbohydrates in a solvent from about 30° C. to about 70° C. to form a supersaturated solution. The solvent may be selected from the group consisting of 1,2-dichloroethane, anisole, glyme, and mixtures thereof. The carbohydrate form a precipitate when the temperature of the solution is lowered and a counter solvent is added. The counter solvent may be selected from the group consisting of methanol, ethanol, toluene, ether, dichloromethane, and mixtures thereof. The resulting carbohydrate crystals are then recovered from the solution and dried.
The nucleobases (R") employed herein are commonly known to organic chemists and no discussion of their synthesis is necessary. However, in order to be useful in the present glycosylation process, the nucleobase derivatives or their tautomeric equivalents bearing amino or hydroxy groups, preferably contain a protecting group, such as amino protecting groups (W) and/or hydroxy protecting groups (Z), depending on the nature of the nucleobase derivative. The protecting group blocks the hydroxy or amino group which may provide a competing reaction site for the alpha-anomer carbohydrate. The protecting groups are attached to the nucleobase derivative (R' ) which is reacted with the beta- or alpha-anomer enriched carbohydrate of formulas II and V and are removed subsequent thereto. A procedure for protecting nucleobase derivatives is described in U.S. Pat. No. 4,526,988.
Preferred amino protecting groups (W) for pyrimidine nucleobase derivatives are selected from the group consisting of silyl ether forming groups such as trialkylsilyl, t-butyldialkylsilyl and t-butyldiarylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl; formyl, acetyl, benzoyl and pivalamido; ether forming groups such as methoxymethyl, t-butyl, benzyl, allyl and tetrahydropyranyl; more preferred is trimethylsilyl. Preferred amino protecting groups (W) for purine nucleobase derivatives are selected from the group consisting of alkylcarboxamides, haloalkylcarboxamides and arylcarboxamides such as 2-trialkylsilylethoxymethyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, t-butyl, phthalamido, tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl ether, methoxythiomethyl, trityl, pivalamido, t-butyldimethylsilyl, t-hexyldimethylsilyl, triisopropylsilyl, trichloroethoxycarbonyl, trifluoroacetyl, naphthoyl, formyl, acetyl; sulfonamides such as alkylsulfonamido and arylsulfonamido, and more preferred is pivalamido. Besides serving as an amino protecting group, the pivalamido protecting group increases the solubility of notoriously insoluble purine nucleobase derivatives and directs the N-glycosidic coupling of the purine bases to the 9 regioisomer as opposed to the 7 regioisomer.
Preferred hydroxy protecting groups (Z) for pyrimidine nucleobase derivatives are selected from silyl ether forming groups such as trialkylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl; carbocyclic esters such as formyl, acetyl, and pivalamido; preferred is trimethylsilyl. Preferred hydroxy protecting groups (Z) for purine nucleobase derivatives are selected from the group consisting of ether forming groups such as benzyl, t-butyl, trityl, tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, trityl; esters such as formyl, acetylpropiorl, pivalamido, benzoyl, substituted benzoyl; carbonates such as carbobenzoxy, t-butoxycarbonyl, carbethoxy, vinyloxycarbonyl; carbamates, such as N,N-dialkylcarbamoyl; trialkylsilyl ethers such as t-butyltrimethylsilyl, t-hexyldimethylsilyl, triisopropylsilyl; more preferred is pivalamido.
In providing protecting groups to the nucleobase derivatives of the present process, the protecting group itself may be protected. For example, N-acetylcytosine may be protected with trimethylsilyl to give bis-trimethylsilyl-N-acetylcytosine.
In addition, it is often advisable to convert any keto oxygen atoms on the nucleobase derivatives to enol form. This makes the nucleobase derivative more aromatic and enhances the reactivity of the nucleobase derivative with the alpha-anomer enriched carbohydrate of formulas II and V. It is most convenient to enolize the keto oxygens and provide silyl protecting groups for them. In a preferred embodiment of the present process the nucleobase derivative (R") is of the formula ##STR15## wherein Z and W are trimethylsilyl.
In accordance with the present process, the nucleobase derivative (R") must be employed in an equimolar amount, relative to the amount of carbohydrate employed. However, it is more preferable to use an excess of nucleobase derivative ranging from about 3 molar equivalents to 30 molar equivalents; more preferably from about 10 molar equivalents to 20 molar equivalents; and most preferably from about 15 molar equivalents to about 20 molar equivalents. In preparing alpha-anomer enriched nucleosides by the present process a smaller amount of nucleobase derivative may be employed in amounts from about 1.5 molar equivalents to about 10 molar equivalents.
Although not critical, it is advisable that the reaction between the beta- and alpha-anomer enriched carbohydrate of formulas II and V and the nucleobase derivative be carried out in a dry atmosphere, e.g. in dry air, nitrogen or argon. This is because certain nucleobase derivatives such as silylated nucleobase derivatives, are moisture sensitive.
The temperature employed in the fusion glycosylation reaction must be sufficient to convert the carbohydrate of formulas II and V and the nucleobase derivative to a molten phase. Therefore, the temperature ranges from about 100° C. to about 160° C. However, a reaction temperature of about 110° C. to about 150° C. is more preferred; while about 130° C. to about 150° C. is most preferred. The glycosylation reaction is preferably carried out under atmospheric conditions and is substantially complete in about 15 minutes to about 2 hours.
The progress of the present fusion glycosylation process may be followed by procedures well known to one of ordinary skill in the art such as high pressure liquid chromatography (HPLC) or thin layer chromatography (TLC) which can be used to detect the presence of nucleoside product.
In accordance with the present fusion glycosylation process, the beta-anomer enriched nucleosides are prepared in an alpha to beta anomer ratio greater than 1:1 to about 9:1.
The final phase of the reaction sequence is the removal of the protecting groups X, Z and/or W from the blocked nucleoside of formula I or IV. The same anomeric ratio of unprotected nucleoside is obtained by removal of the protecting groups.
Most silyl and silyl-amino protecting groups are easily cleaved by use of a protic solvent, such as water or an alcohol. The acyl protecting groups, such as benzoyl and the acyl-amino protecting groups, are removed by hydrolysis with a strong base at a temperature from about 0° C. to about 100° C. Strong or moderately strong bases suitable for use in this reaction are bases which have a pKa (at 25° C.) of about 8.5 to about 20.0. Such bases include alkali metal hydroxides such as sodium or potassium hydroxide; alkali metal alkoxides such as sodium methoxide or potassium t-butoxide; alkali metal amides; amines such as diethylamine, hydroxylamine, ammonia and the like; and other common bases such as hydrazine and the like. At least one equivalent of base is needed for each protecting group.
The acyl protecting groups can also be removed with acid catalysts, such as methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or with acidic ion exchange resins. It is preferred to carry out such hydrolysis at relatively high temperature, such as the reflux temperature of the mixture, but temperatures as low as ambient may be used when particularly strong acids are used.
The removal of ether protecting groups is carried out by known methods, for example, with ethanethiol and aluminum chloride.
The t-butyldimethylsilyl protecting group requires acid conditions, such as contact with gaseous hydrogen halide, for its removal.
Removal of the protecting groups may be conveniently carried out in alcoholic solvents, especially aqueous alkanols such as methanol. However, the deblocking reaction may also be carried out in any convenient solvent, such as polyols including ethylene glycol, ethers such as tetrahydrofuran, ketones such as acetone and methyl ethyl ketone, or dimethylsulfoxide.
In a preferred embodiment, the deblocking reaction employs ammonia to remove a benzoyl hydroxy-protecting group at a temperature of about 10° C. It is preferable, however, to use an excess of base in this reaction, although the amount of excess base used is not crucial.
The resulting beta-anomer enriched nucleosides of formula VI or VII may be extracted and/or isolated from the reaction mixture by the procedure described in U.S. Pat. No. 4,965,374, which is incorporated herein by reference.
The following examples illustrate specific aspects of the present invention and are not intended to limit the scope thereof in any respect and should not be so construed.
Example 1 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 3 equivalents of bistrimethylsilylcytosine
Bis-trimethylsilylcytosine was prepared by combining 292 mg of cytosine with 2 ml of hexamethyldisilazane, 11 mg of ammonium sulfate and 5 ml of xylenes and refluxing the solution for one hour to form a homogenous solution. The excess xylenes and hexamethyldisilazane were removed leaving behind a molten residue of bis-trimethylsilylcytosine. 400 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate, dissolved in 2 ml of xylenes, were added to the molten bis-trimethylsilylcytosine and the xylenes were removed. The temperature of the reaction mixture was maintained at 160° C. for 15 minutes. HPLC analysis confirmed completion of the reaction. The alpha to beta anomeric ratio of blocked nucleoside product was 1:1.3.
To extract the nucleoside product, the reaction mixture was cooled, diluted in 50 ml of ethyl acetate and washed with 50 ml of 1 N hydrochloric acid.
Example 2 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-ketopyrimidin-2-one with 3 equivalents of bistrimethylsilyluracil
Bis-trimethylsilyluracil was prepared by combining 295 mg of uracil with 5 ml of hexamethyldisilazane, 11 mg of ammonium sulfate and 10 ml of 1,2-dichloroethane. The solution was heated to 110° C. for one hour to form a homogenous solution and the excess xylenes and hexamethyldisilazane were removed to form molten bis-trimethylsilyluracil. 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate were added to the molten bis-trimethylsilyluracil. The temperature of the reaction mixture was maintained at 150° C. for 2 hours. HPLC analysis confirmed completion of the reaction. The alpha to beta anomeric ratio of blocked nucleoside product was 1:1.8.
To extract the nucleoside product, the reaction mixture was cooled, diluted in 50 ml of ethyl acetate and washed with 50 ml of 1N hydrochloric acid.
Example 3 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 10 equivalents of bistrimethylsilylcytosine
To 1.12 g of molten bis-trimethylsilylcytosine were added 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate. The temperature of the reaction mixture was maintained at 130° C. for 1 hour. HPLC analysis confirmed completion of the reaction. The anomeric ratio of the blocked nucleoside product was 1.7:1 beta to alpha.
To extract the nucleoside product, the reaction mixture was diluted with 100 ml ethyl acetate and washed with 100 ml of 1N hydrochloric acid. A quantitative HPLC analysis of the organic layer indicated that the yield of blocked beta-anomer nucleoside was 50 percent.
Example 4 Preparation of alpha-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 1.5 equivalents of bistrimethylsilylcytosine
To 383 mg of bis-trimethylsilylcytosine were added 500 mg in a 50:50 alpha to beta anomeric mixture of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-methanesulfonate. The temperature of the reaction mixture was maintained at 130° C. for 2 hours. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1:3.
Example 5 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-acetamidopyrimidin-2-one with 3 equivalents of bis-trimethylsilyl-N-acetylcytosine
To 500 mg of bis-trimethylsilyl-N-acetylcytosine were added 980 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate. The temperature of the reaction mixture was maintained at 108° C. for 3 hours. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1.4:1.
To extract the nucleoside product, the reaction mixture was cooled, diluted with 25 ml ethyl acetate and washed with 25 ml of 1 N hydrochloric acid. The aqueous layer was washed with 30 ml of ethyl acetate. A quantitative HPLC analysis of the ethyl acetate layer indicated that the yield of blocked beta-anomer nucleoside was 34 percent.
Example 6 Preparation of alpha-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 3 equivalents of bistrimethylsilylcytosine
To 332 mg of bis-trimethylsilylcytosine were added 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5- dibenzoyl-1-D-methanesulfonate. The temperature of the reaction mixture was maintained at 130° C. for 1 hour. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1:6.3.
To extract the nucleoside product, the reaction mixture was cooled, diluted with 20 ml ethyl acetate and washed with 20 ml of 1N hydrochloric acid. The ethyl acetate layer was washed with 20 ml of water. A quantitative HPLC analysis of the ethyl acetate layer indicated that the yield of blocked alpha-anomer nucleoside was 80 percent.
Example 7 Preparation of alpha-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 1.5 equivalents of bistrimethylsilylcytosine
To 358 mg of bis-trimethylsilyl-cytosine were added 500 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-β-toluenesulfonate. The temperature of the reaction mixture was maintained at 140° C. for 30 minutes. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1:4.9.
To extract the nucleoside product, the reaction mixture was cooled, diluted with 50 ml ethyl acetate and washed with 50 ml of 1N hydrochloric acid.
Example 8 Preparation of alpha-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 1.5 equivalents of bistrimethylsilylcytosine
To 358 mg of molten bis-trimethylsilylcytosine were added 500 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-β-toluenesulfonate. The temperature of the reaction mixture was maintained at 130° C. for 2 hours. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1:4.8.
To extract the nucleoside product, the reaction mixture was cooled, diluted with 100 ml ethyl acetate and washed with 100 ml of 1N hydrochloric acid.
Example 9 Preparation of alpha-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-acetamidopyrimidin-2-one with 3 equivalents of bis-trimethylsilyl-N-acetylcytosine
To 500 mg of bis-trimethylsilyl-N-acetylcytosine were added 980 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-β-methanesulfonate. The temperature of the reaction mixture was maintained at 105°-108° C. for 3 hours. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 1:7.
To extract the nucleoside product, the reaction mixture was cooled, diluted with 25 ml ethyl acetate and washed with 25 ml of 1N hydrochloric acid. The two layers were separated and the aqueous layer was washed with 30 ml of ethyl acetate. A quantitative HPLC analysis of the combined ethyl acetate layers indicated that the yield of blocked alpha-anomer nucleoside was 75 percent.
Example 10 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-acetamidopyridin-2-one with 3 equivalents of bis-trimethylsilyl-N-acetylcytosine
To 393 mg of molten bis-trimethylsilyl-N-acetylcytosine were added 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate- The temperature of the reaction mixture was maintained at 110° C. for 1 hour. The beta to alpha anomeric ratio of the blocked nucleoside product was 2.3:1.
To extract the nucleoside product, the reaction mixture was diluted with 40 ml ethyl acetate and washed with 25 ml of 1N hydrochloric acid. A quantitative HPLC analysis of the organic layer indicated that the yield of beta-anomer nucleoside was 27 percent.
Example 11 Preparation of beta-anomer enriched 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 20 equivalents of bistrimethylsilylcytosine
Bis-trimethylsilylcytosine was prepared by combining 4.9 g of cytosine with 90 ml of hexamethyldisilazane, 581 mg of ammonium sulfate and 2 ml of xylenes and heating the solution for two hours to form a homogenous solution. The excess hexamethyldisilazane was removed and a white residue formed. 1 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-α-methanesulfonate, dissolved in 5 ml of acetonitrile, was added to the bis-trimethylsilylcytosine solution and the acetonitrile removed. The temperature of the reaction mixture was maintained at 130° C. under vacuum for 1 hour. HPLC analysis confirmed completion of the reaction. The beta to alpha anomeric ratio of the blocked nucleoside product was 3.9:1.
To extract the nucleoside product, the reaction mixture was diluted with 100 ml dichloromethane and washed sequentially with 100 ml of 1N hydrochloric acid and 200 ml of 5% sodium bicarbonate followed by 200 ml of saturated sodium chloride. The organic layer was dried over magnesium sulfate, filtered and evaporated to 1.03 g of a yellow solid. A quantitative HPLC analysis indicated that the yield of beta-anomer nucleoside was 43 percent.
The following Table shows how the carbohydrate selected, reaction temperature and molar equivalents of nucleobase effect the yield and anomeric ratio of the nucleoside product.
                                  TABLE                                   
__________________________________________________________________________
                  Base    α/β                                  
                  (R')    Nucleoside                                      
Example                                                                   
     Carbo. Base (R')                                                     
                  Equiv.                                                  
                      Temp.                                               
                          Ratio Yield                                     
__________________________________________________________________________
7    β-OTs                                                           
            Cytosine                                                      
                  1.5 127° C.                                      
                          5:1   N/D                                       
6    β-OMs                                                           
            Cytosine                                                      
                  3.0 130° C.                                      
                          6:1   80% α                               
9    β-OMs                                                           
            N-Acetyl-                                                     
                  3.0 127° C.                                      
                          7:1   75% α                               
            Cytosine                                                      
4    1:1 α:β-OMs                                               
            Cytosine                                                      
                  1.5 130° C.                                      
                          3:1   N/D                                       
1    α-OMs                                                          
            Cytosine                                                      
                  3.0 160° C.                                      
                          1:1.3 N/D                                       
3    α-OMs                                                          
            Cytosine                                                      
                  10.0                                                    
                      130° C.                                      
                          1:1.7 50% β                                
2    α-OMs                                                          
            Uracil                                                        
                  3.0 150° C.                                      
                          1:1.8 N/D                                       
5    α-OMs                                                          
            N-Acetyl-                                                     
                  3.0 115° C.                                      
                          1:1.4 34% β                                
            Cytosine                                                      
OMs  α                                                              
     N-Acetyl-                                                            
            3.0   110° C.                                          
                      1:2.3                                               
                          27% β                                      
OMs  α                                                              
     Cytosine                                                             
            20.0  130° C.                                          
                      1:4 43% β                                      
__________________________________________________________________________
 (N/D) means not determined. The carbohydrates (carbo.) are hydroxy
 protected. α- or β-OMs is alpha- or
 beta-2,2-difluoro-2-deoxy-D-ribofuranosyl-3,5-dibenzoyl-1-methanesulfonate
 and β- or α-OTs is beta- or alpha-
 2,2-difluoro-2-deoxy-D-ribofuranosyl-3,5-dibenzoyl-1-toluenesulfonate. The
 yields are based on the total amount of carbohydrate and were calculated
 from a quantitative reverse phase HPLC analysis, wherein the corresponding
 solution product peak was compared with a standard,
 1-(2'-deoxy-2',2'-difluoro-3',5'-di-O-benzoyl-beta-D-ribofuranosyl)-4-amin
opyrimidin-2-one. The nucleoside base protecting group in each example is
 trimethylsilyl.
The present invention has been described in detail, including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of the present disclosure, may make modifications and/or improvements on this invention that fall within the scope and spirit of the invention as set forth in the following claims.

Claims (18)

What is claimed is:
1. A stereoselective fusion glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR16## wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase selected from the group consisting of ##STR17## wherein R1 is selected from the group consisting of hydrogen C1 -C7 alkyl arid halo; R2 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo; Z is a hydroxy protecting group and W is an amino protecting group; comprising reacting alpha-anomer 2,2-difluorocarbohydrate in a anomer ratio of greater than 1:1 alpha to beta of the formula ##STR18## wherein Y is selected from the group consisting of C1 -C7 alkylsulfonyloxy, arylsulfonyloxy, substituted C1 -C7 alkylsulfonyloxy and substituted arylsulfonyloxy and X is as defined above; with at least 3 molar equivalents; of a nucleobase derivative R" selected from the group consisting of ##STR19## wherein R1, R2, Z and W are as defined above; at a temperature ranging from about 100° C. to about 160° C. in the absence of a catalyst and a solvent.
2. The process of claim 1 wherein the amount of R" is greater than 3 molar equivalents to about 30 molar equivalents.
3. The process of claim 1 wherein Y is selected from the group consisting of methanesulfonyloxy, 2-chloroethanesulfonyloxy, toluenesulfonyloxy, p-nitrobenzenesulfonyloxy and p-bromobenzenesulfonyloxy.
4. The process of claim 1 wherein X is selected from the group consisting of benzoyl; benzoyl substituted by a group selected from the group consisting of cyano, halo, carbo C1 -C7 alkoxy, toluoyl, nitro, C1 -C7 alkoxy, C1 -C7 alkyl and diC1 -C7 alkylamino; and benzoyl di-substituted by groups independently selected from the group consisting of cyano, halo, carbo C1 -C7 alkoxy, soluoyl, nitro, C1 -C7 alkyl and diC1 -C7 alkylamino.
5. The process of claim 1 wherein Z and W are selected from the group consisting of triC1 -C7 alkylsilyl, t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, formyl and acetyl.
6. The process of claim 5 wherein Z and W are trimethylsilyl.
7. The process of claim 1 wherein R" is of the formula ##STR20## wherein Z and W are trimethylsilyl.
8. The process of claim 7 wherein Y is methanesulfonyloxy.
9. The process of claim 7 wherein X is benzoyl.
10. A stereoselective glycosylation process for preparing a beta-anomer enriched nucleoside of the formula ##STR21## wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase selected from the group consisting of ##STR22## wherein R1 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo; R2 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo; Z is a hydroxy protecting group and W is an amine protecting group; comprising reacting alpha-anomer 2-fluorocarbohydrate in a anomer ratio of greater than 1:1 alpha to beta of the formula ##STR23## wherein Y i8 selected from the group consisting of C1 -C7 alkylsulfonyloxy, arylsulfonyloxy, substituted C1 -C7 alkylsulfonyloxy and substituted arylsulfonyloxy and X is as defined above; with at least 3 molar equivalents of a nucleobase derivative, R" selected from the group consisting of ##STR24## wherein R1, R2, Z and W are as defined above; at a temperature ranging from about 100° C. to about 160° C. in the absence of a catalyst and a solvent.
11. The process of claim 10 wherein the amount of R" is greater than 3 molar equivalents to about 30 molar equivalents.
12. The process of claim 10 wherein Y is selected from the group consisting of methanesulfonyloxy, 2-chloroethanesulfonyloxy, toluenesulfonyloxy, p-nitrobenzenesulfonyloxy and p-bromobenzenesulfonyloxy.
13. The process of claim 10 wherein X is selected from the group consisting of benzoyl; benzoyl substituted by a group selected from the group consisting of cyano, halo, carbo C1 -C7 alkoxy, toluoyl, nitro, C1 -C7 alkoxy, C1 -C7 alkyl and diC1 -C7 alkylamino; and benzoyl di-substituted by groups independently selected from the group consisting of cyano, halo, carbo C1 -C7 alkoxy, toluoyl, nitro, C1 -C7 alkoxy, C1 -C7 alkyl and diC1 -C7 alkylamino.
14. The process of claim 10 wherein Z and W are selected from the group consisting of triC1 -C7 alkylsilyl, t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, formyl and acetyl.
15. The process of claim 14 wherein Z and W are trimethylsilyl.
16. The process of claim 1 further comprising deblocking to form a beta-anomer enriched nucleoside of the formula ##STR25## wherein R is a deblocked nucleobase selected from the group consisting of ##STR26## wherein R1 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo; R2 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo.
17. The process of claim 16 wherein R is of the formula ##STR27##
18. The process of claim 10 further comprising deblocking to form a beta-anomer enriched nucleoside of the formula ##STR28## wherein R is a deblocked nucleobase selected from the group consisting of ##STR29## wherein R1 is selected from the group consisting of hydrogen, C7 alkyl and halo; R2 is selected from the group consisting of hydrogen, C1 -C7 alkyl and halo.
US08/044,343 1992-06-22 1993-04-07 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides Expired - Lifetime US5401838A (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
US08/044,343 US5401838A (en) 1992-06-22 1993-04-07 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
UA93003070A UA41261C2 (en) 1992-06-22 1993-06-18 METHOD OF OBTAINING BETA-ANOMER-ENRICHED NUCLEOSIDES
AU41355/93A AU659009B2 (en) 1992-06-22 1993-06-18 Stereoselective glycosylation process
MYPI93001200A MY115775A (en) 1992-06-22 1993-06-19 Stereoselective glycosylation process
CY206793A CY2067A (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
HU9301822A HUT64358A (en) 1992-06-22 1993-06-21 A stereoselective glycosyling procedure
KR1019930011312A KR100252452B1 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
AT93304817T ATE158799T1 (en) 1992-06-22 1993-06-21 METHOD FOR STEREOSELECTIVE GLYCOSYLATION
SG9607939A SG94686A1 (en) 1992-06-22 1993-06-21 Stereoselective gylcosylation process
NZ247939A NZ247939A (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process for the preparation of a beta anomer enriched nucleoside
NO19932288A NO180235B3 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
EP93304817A EP0577303B1 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
DE69314239T DE69314239C5 (en) 1992-06-22 1993-06-21 Method for stereoselective glycosylation
IL106071A IL106071A (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process for preparing beta-anomer enriched 2'-deoxy-2'-fluoro (and 2',2'-difluoro)-ribofuranosyl nucleosides
CN 93109045 CN1040114C (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
ES93304817T ES2107624T3 (en) 1992-06-22 1993-06-21 STEREOSELECTIVE GLUCOSILATION PROCEDURE.
CZ19931233A CZ291165B6 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
MX9303707A MX9303707A (en) 1992-06-22 1993-06-21 STEREOSELECTIVE GLUCOSILATION PROCESS TO PREPARE 2'-DEOXIFLUORONUCLEUSIDS.
PL93299415A PL172348B1 (en) 1992-06-22 1993-06-21 Method for the production of nucleosides PL PL PL PL PL PL PL
CA002098881A CA2098881C (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
FI932869A FI108643B (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process to prepare a nucleoside enriched for the beta anomer
BR9302434A BR9302434A (en) 1992-06-22 1993-06-21 PROCESS TO PREPARE AN ENRICHED NUCLEOSIDE WITH BETA-ANOMER
JP14913093A JP3313191B2 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation method
DK93304817.5T DK0577303T3 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation process
HU0201196A HU223837B1 (en) 1992-06-22 1993-06-21 Stereoselective glycosylation procedure
HK97102088A HK1000535A1 (en) 1992-06-22 1997-11-04 Stereoselective glycosylation process
GR970403339T GR3025689T3 (en) 1992-06-22 1997-12-16 Stereoselective glycosylation process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/902,312 US5371210A (en) 1992-06-22 1992-06-22 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US08/044,343 US5401838A (en) 1992-06-22 1993-04-07 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/902,312 Continuation-In-Part US5371210A (en) 1992-06-22 1992-06-22 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides

Publications (1)

Publication Number Publication Date
US5401838A true US5401838A (en) 1995-03-28

Family

ID=46247897

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/044,343 Expired - Lifetime US5401838A (en) 1992-06-22 1993-04-07 Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides

Country Status (1)

Country Link
US (1) US5401838A (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives
US20030023078A1 (en) * 2000-02-18 2003-01-30 Montgomery John A. Method for synthesizing 2-chloro-9-(2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine
US20040142857A1 (en) * 2002-11-04 2004-07-22 Gallop Mark A. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20050288363A1 (en) * 1998-06-19 2005-12-29 Trustees Of Dartmouth College Therapeutic compositions and methods of use
WO2006063105A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
US20060217547A1 (en) * 2005-03-04 2006-09-28 Maikap Golak C Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides
US20070015914A1 (en) * 2005-05-02 2007-01-18 Ko-Chung Lin Stereoselective synthesis of beta-nucleosides
US20070042987A1 (en) * 2004-07-30 2007-02-22 Ko-Chung Lin Stereoselective synthesis of beta-nucleosides
US20070155742A1 (en) * 2002-01-15 2007-07-05 Tadashi Honda Tricyclic-bis-enone derivatives and methods of use thereof
US20080233195A1 (en) * 2006-11-17 2008-09-25 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US20080261985A1 (en) * 2006-11-17 2008-10-23 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US20090093447A1 (en) * 2000-11-28 2009-04-09 Marina Konopleva Cddo-compounds and combination therapies thereof
US20090124797A1 (en) * 2007-11-06 2009-05-14 Pharmaessentia Corporation Novel synthesis of beta-nucleosides
US20090326063A1 (en) * 2008-01-11 2009-12-31 Sporn Michael B Synthetic triterpenoids and methods of use in the treatment of disease
US20100041904A1 (en) * 2008-04-18 2010-02-18 Xin Jiang Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US20100048911A1 (en) * 2008-04-18 2010-02-25 Xin Jiang Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20100048887A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Compounds including an anti-inflammatory pharmacore and methods of use
US20100056777A1 (en) * 2008-04-18 2010-03-04 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US20100069625A1 (en) * 2007-03-23 2010-03-18 Dongwoo Syntech Co., Ltd Process for preparing of 2'-deoxy-2'2'-difluorocytidine
US20100179314A1 (en) * 2007-05-31 2010-07-15 Nanjing Cavendish Bio-Engineering Technology Co., Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof
US20110196007A1 (en) * 2008-07-22 2011-08-11 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
WO2013151774A1 (en) 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US20140024612A1 (en) * 2012-07-19 2014-01-23 Oncogenex Pharmaceuticals, Inc. Fluorinated pyrimidine analogs and methods of use thereof
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US9205113B2 (en) 2012-05-08 2015-12-08 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US9919060B2 (en) 2009-05-01 2018-03-20 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US4145531A (en) * 1976-06-23 1979-03-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for producing 2'-substituted-D-ribofuranosyl purine compounds
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
GB2125401A (en) * 1982-08-17 1984-03-07 Sandoz Ltd Desoxyuridine derivatives and their use as pharmaceuticals
EP0145978A2 (en) * 1983-11-18 1985-06-26 Bristol-Myers Company Nucleoside process
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0211354A2 (en) * 1985-07-29 1987-02-25 Merrell Dow Pharmaceuticals Inc. Nucleosides and their use as antineoplastic agents
EP0219829A2 (en) * 1985-10-18 1987-04-29 Sloan-Kettering Institute For Cancer Research 2-Fluoro-arabinofuranosyl purine nucleosides
EP0345751A1 (en) * 1988-06-08 1989-12-13 Merrell Dow Pharmaceuticals Inc. Anti-retroviral diflourinated nucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0399161A2 (en) * 1989-04-17 1990-11-28 International Business Machines Corporation Multi-level circuit card structure
EP0428109A2 (en) * 1989-11-13 1991-05-22 Bristol-Myers Squibb Company Deoxyfluoronucleoside process

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US4145531A (en) * 1976-06-23 1979-03-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for producing 2'-substituted-D-ribofuranosyl purine compounds
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
GB2125401A (en) * 1982-08-17 1984-03-07 Sandoz Ltd Desoxyuridine derivatives and their use as pharmaceuticals
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
EP0145978A2 (en) * 1983-11-18 1985-06-26 Bristol-Myers Company Nucleoside process
EP0211354A2 (en) * 1985-07-29 1987-02-25 Merrell Dow Pharmaceuticals Inc. Nucleosides and their use as antineoplastic agents
EP0219829A2 (en) * 1985-10-18 1987-04-29 Sloan-Kettering Institute For Cancer Research 2-Fluoro-arabinofuranosyl purine nucleosides
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0345751A1 (en) * 1988-06-08 1989-12-13 Merrell Dow Pharmaceuticals Inc. Anti-retroviral diflourinated nucleosides
EP0399161A2 (en) * 1989-04-17 1990-11-28 International Business Machines Corporation Multi-level circuit card structure
EP0428109A2 (en) * 1989-11-13 1991-05-22 Bristol-Myers Squibb Company Deoxyfluoronucleoside process

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Chem. Abstracts , 56, 11692 93 (1962). *
Chem. Abstracts, 56, 11692-93 (1962).
Griengl, et al., J. Med. Chem. , 28(11), 1679 84 (1985). *
Griengl, et al., J. Med. Chem., 28(11), 1679-84 (1985).
Hoffer, Chem. Ber. , 93, 2777 81 (1960). *
Hoffer, Chem. Ber., 93, 2777-81 (1960).
Howell, et al., J. Org. Chem. , 53, 85 88 (1988). *
Howell, et al., J. Org. Chem., 53, 85-88 (1988).
Hubbard, et al., Nucleic Acids Res. , 12(17), 6827 37 (1984). *
Hubbard, et al., Nucleic Acids Res., 12(17), 6827-37 (1984).
Kazimierczuk, et al., Nucleic Acids Res. , 12(2), 1179 92 (1984). *
Kazimierczuk, et al., Nucleic Acids Res., 12(2), 1179-92 (1984).
R. P. Hodge, et al., J. Org. Chem. , 56, 1553 64 (1991). *
R. P. Hodge, et al., J. Org. Chem., 56, 1553-64 (1991).
Shimadate, et al., Nippon Kagaku Zasshi , 82, 1268 70 (1961). *
Shimadate, et al., Nippon Kagaku Zasshi, 82, 1268-70 (1961).
Shimdate, et al., Nippon Kagaku Zasshi , 81, 1440 41 (1960). *
Shimdate, et al., Nippon Kagaku Zasshi, 81, 1440-41 (1960).
Tann, et al., J. Org. Chem. , 50, 3644 47 (1985). *
Tann, et al., J. Org. Chem., 50, 3644-47 (1985).
Vorbruggen, et al., J. Org. Chem. , 41(12), 2084 86 (1976). *
Vorbruggen, et al., J. Org. Chem., 41(12), 2084-86 (1976).

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5608043A (en) * 1995-02-03 1997-03-04 Eli Lilly And Company Process for the preparation of 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose compounds
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives
US20080220057A1 (en) * 1998-06-19 2008-09-11 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US8586775B2 (en) 1998-06-19 2013-11-19 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7863327B2 (en) 1998-06-19 2011-01-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20080234368A9 (en) * 1998-06-19 2008-09-25 Trustees Of Dartmouth College Therapeutic compositions and methods of use
US8034955B2 (en) 1998-06-19 2011-10-11 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20050288363A1 (en) * 1998-06-19 2005-12-29 Trustees Of Dartmouth College Therapeutic compositions and methods of use
US20030023078A1 (en) * 2000-02-18 2003-01-30 Montgomery John A. Method for synthesizing 2-chloro-9-(2-fluoro-beta-d-arabinofuranosyl)-9h-purin-6-amine
US20050288500A1 (en) * 2000-02-18 2005-12-29 Southern Research Institute Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-B-D-arabinofuranosyl)-9H-purin-6-amine
US7470784B2 (en) 2000-02-18 2008-12-30 Southern Research Institute Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine
US6949640B2 (en) 2000-02-18 2005-09-27 Southern Research Institute Method for synthesizing 2-chloro-9-(2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine
US20090093447A1 (en) * 2000-11-28 2009-04-09 Marina Konopleva Cddo-compounds and combination therapies thereof
US7795305B2 (en) 2000-11-28 2010-09-14 Board Of Regents, The University Of Texas System CDDO-compounds and combination therapies thereof
US20070155742A1 (en) * 2002-01-15 2007-07-05 Tadashi Honda Tricyclic-bis-enone derivatives and methods of use thereof
US7678830B2 (en) 2002-01-15 2010-03-16 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US8067465B2 (en) 2002-01-15 2011-11-29 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US7608602B2 (en) 2002-11-04 2009-10-27 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20040142857A1 (en) * 2002-11-04 2004-07-22 Gallop Mark A. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20080021208A1 (en) * 2002-11-04 2008-01-24 Xenoport, Inc. Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof
US7803785B2 (en) 2002-11-04 2010-09-28 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20100016254A1 (en) * 2002-11-04 2010-01-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2004041203A3 (en) * 2002-11-04 2005-04-21 Xenoport Inc Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20070042987A1 (en) * 2004-07-30 2007-02-22 Ko-Chung Lin Stereoselective synthesis of beta-nucleosides
WO2006063105A1 (en) * 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
US20060173174A1 (en) * 2004-12-08 2006-08-03 Anne-Ruth Born Difluoronucleosides and process for preparation thereof
JP2007522151A (en) * 2004-12-08 2007-08-09 シコール インコーポレイティド Difluoronucleoside and process for preparing the same
US20060217547A1 (en) * 2005-03-04 2006-09-28 Maikap Golak C Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides
US7235647B2 (en) * 2005-03-04 2007-06-26 Dabur Pharma Limited Intermediate and process for preparing of β- anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranosyl nucleosides
US20070208170A1 (en) * 2005-03-04 2007-09-06 Dabur Pharma Limited Intermediate and process for preparing of beta- anomer enriched 21-deoxy,21,21-difluoro-d-ribofuranosyl nucleosides
US7485716B2 (en) 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
US20070015914A1 (en) * 2005-05-02 2007-01-18 Ko-Chung Lin Stereoselective synthesis of beta-nucleosides
US20110009363A1 (en) * 2006-11-17 2011-01-13 Tadashi Honda Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US20080233195A1 (en) * 2006-11-17 2008-09-25 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8067394B2 (en) 2006-11-17 2011-11-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
US20080261985A1 (en) * 2006-11-17 2008-10-23 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US7994310B2 (en) 2007-03-23 2011-08-09 Dongwoo Syntech Co., Ltd. Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
US20100069625A1 (en) * 2007-03-23 2010-03-18 Dongwoo Syntech Co., Ltd Process for preparing of 2'-deoxy-2'2'-difluorocytidine
US20100179314A1 (en) * 2007-05-31 2010-07-15 Nanjing Cavendish Bio-Engineering Technology Co., Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof
US8324373B2 (en) 2007-05-31 2012-12-04 Nanjing Cavendish Bio-Engineering Technology Co., Ltd. Highly stereoselective process for preparing gemcitabine and intermediates thereof
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US20090124797A1 (en) * 2007-11-06 2009-05-14 Pharmaessentia Corporation Novel synthesis of beta-nucleosides
US8193339B2 (en) 2007-11-06 2012-06-05 Pharmaessentia Corp. Synthesis of β-nucleosides
US8129429B2 (en) 2008-01-11 2012-03-06 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
US20090326063A1 (en) * 2008-01-11 2009-12-31 Sporn Michael B Synthetic triterpenoids and methods of use in the treatment of disease
US8455544B2 (en) 2008-01-11 2013-06-04 Reata Pharmaecuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
US8394967B2 (en) 2008-04-18 2013-03-12 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
USRE45325E1 (en) 2008-04-18 2015-01-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8124656B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US12358866B2 (en) 2008-04-18 2025-07-15 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8258329B2 (en) 2008-04-18 2012-09-04 Reata Pharmaceuticals, Inc. Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
US7943778B2 (en) 2008-04-18 2011-05-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US11919838B2 (en) 2008-04-18 2024-03-05 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8338618B2 (en) 2008-04-18 2012-12-25 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20100056777A1 (en) * 2008-04-18 2010-03-04 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8440820B2 (en) 2008-04-18 2013-05-14 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8440854B2 (en) 2008-04-18 2013-05-14 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
US20100041904A1 (en) * 2008-04-18 2010-02-18 Xin Jiang Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US11091430B2 (en) 2008-04-18 2021-08-17 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20100048911A1 (en) * 2008-04-18 2010-02-25 Xin Jiang Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US10556858B2 (en) 2008-04-18 2020-02-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US20100048887A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Compounds including an anti-inflammatory pharmacore and methods of use
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US10093614B2 (en) 2008-04-18 2018-10-09 Reata Pharmaceuticals, Inc. Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9796668B2 (en) 2008-04-18 2017-10-24 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9670147B2 (en) 2008-04-18 2017-06-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US20110196007A1 (en) * 2008-07-22 2011-08-11 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
US8314137B2 (en) 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US9000188B2 (en) 2008-07-22 2015-04-07 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US9919060B2 (en) 2009-05-01 2018-03-20 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
US10137104B2 (en) 2012-04-04 2018-11-27 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
WO2013151774A1 (en) 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US9539287B2 (en) 2012-05-08 2017-01-10 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9205113B2 (en) 2012-05-08 2015-12-08 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US20140024612A1 (en) * 2012-07-19 2014-01-23 Oncogenex Pharmaceuticals, Inc. Fluorinated pyrimidine analogs and methods of use thereof
US9493500B2 (en) * 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Similar Documents

Publication Publication Date Title
US5401838A (en) Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5744597A (en) Stereoselective anion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
EP0577303B1 (en) Stereoselective glycosylation process
JP3462893B2 (en) Methods for anomerizing nucleosides
US5594124A (en) Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
JP2005504036A (en) Method for preparing purine nucleosides
CA2442979C (en) Process for the preparation of 2'-halo-.beta.-l-arabinofuranosyl nucleosides
US5424416A (en) Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
AU2002303187A1 (en) Process for the preparation of 2'-HALO-Beta-L-arabinofuranosyl nucleosides
EP0389110B1 (en) Process for the preparation of 2'-deoxy-5-trifluoromethyl-beta-uridine
US5466787A (en) Process for preparing AZT
Napoli et al. Synthetic studies on the glycosylation of the base residues of inosine and uridine
JPH0597885A (en) Process for the production of 2-deoxy-D-threo-pentofuranoside, their production intermediates and their use
AU659008B2 (en) Stereoselective anion glycosylation process
JPH01224390A (en) Production of nucleoside derivative
AU659009B2 (en) Stereoselective glycosylation process
HK1000535B (en) Stereoselective glycosylation process
HK1000535A1 (en) Stereoselective glycosylation process

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: ELI LILLY AND COMPANY, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHOU, TA-SEN;REEL/FRAME:007080/0866

Effective date: 19930407

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12